Trial Profile
A Phase Ib/II, Open-Label, Multicenter Study With a Non-Randomized Stage Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab Plus Lenalidomide (+Len), and a Randomized Stage Evaluating the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Patients With Follicular Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Mosunetuzumab (Primary) ; Mosunetuzumab (Primary) ; Tocilizumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
- 12 Dec 2023 Results assessing preliminary safety, efficacy, and biomarker data from this ongoing trial of Mosunetuzumab (subcutaneous) combined with oral Lenalidomide in patients with 1L Follicular Lymphoma who require systemic therapy, were presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 10 Nov 2023 The study protocol amended as trial phase changed from phase 1 to phase Ib/II.
- 10 Nov 2023 Status changed from recruiting to active, no longer recruiting.